Anti-cyclic citrullinated peptide antibody determination kit and preparation method thereof

Through the dual reagent method and latex microsphere technology, the cumbersome and low efficiency of anti-cyclic citrulline peptide antibody detection is solved, efficient and accurate detection is achieved, suitable for automated systems, and costs are reduced.

CN118937661APending Publication Date: 2024-11-12DAAN GENE CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202310529646.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing anti-cyclic citrulline peptide antibody detection methods are cumbersome, low efficiency, low accuracy and high cost, and cannot meet the needs of fast, automated and efficient detection.

Method used

By using the dual reagent method, the anti-cyclic citrulline peptide antibody assay kit is formed by formulating reagent R1 and reagent R2, and the antigen-coated latex microspheres are used to specifically bind to the antibody, which significantly improves detection sensitivity and stability. Suitable for fully automatic biochemical analyzers.

Benefits of technology

It simplifies detection operations, improves detection efficiency and accuracy, reduces costs, and is suitable for large-scale automated testing, significantly improving the stability of reagents and the stability of detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004224114710000091
    Figure BDA0004224114710000091
  • Figure BDA0004224114710000101
    Figure BDA0004224114710000101
  • Figure BDA0004224114710000103
    Figure BDA0004224114710000103
Patent Text Reader

Abstract

The invention belongs to the technical field of medical examination and determination, and relates to an anti-cyclic citrullinated peptide antibody determination kit and a preparation method thereof, the anti-cyclic citrullinated peptide antibody determination kit comprises a reagent R1 and a reagent R2; the reagent R1 comprises the following components: a first buffer solution, inorganic salt ions, an osmotic pressure regulator, a surfactant and a first preservative; the reagent R2 comprises latex microspheres coated with anti-cyclic citrullinated peptide antigens, a sealing agent, a second preservative, a second buffer solution and a stabilizer. According to the technical scheme, the stability of the reagent can be improved, the stability of the detection result is higher, the detection sensitivity is high, and operation is easy and convenient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of medical testing and determination, and more specifically, to an anti-cyclic citrullinated peptide antibody determination kit and a preparation method thereof. Background Art

[0002] Rheumatoid arthritis (RA) is one of the most common chronic inflammatory and autoimmune diseases, with a global incidence of 0.5-1.0%. Its pathological manifestations include chronic inflammation of the synovial membrane, pannus formation, cartilage and bone destruction in the joints, and can cause a variety of complications, such as neurological diseases, pericarditis, lymphadenitis, etc. Therefore, early and clear diagnosis of rheumatoid arthritis helps clinicians use disease-modifying drugs to control the disease and effectively reduce the occurrence of joint erosion.

[0003] Anti-cyclic citrullinated peptide antibody (Anti-CCP) is a polypeptide fragment of cyclic filaggrin and is mainly an IgG type antibody. Clinical studies have shown that Anti-CCP has good sensitivity and specificity for rheumatoid arthritis (RA) and is associated with the activity and progression of RA. The detection of anti-cyclic citrullinated peptide antibody is highly specific for the diagnosis of rheumatoid arthritis and can be used for the early diagnosis of RA.

[0004] Currently, there are two methods for detecting anti-cyclic citrullinated peptide antibodies:

[0005] Enzyme-Linked Immuno Sorbent Assay (ELISA). This method is generally operated manually, which is cumbersome and inefficient, resulting in a greater human influence on the test results. At the same time, this method is expensive for a single batch of samples. Therefore, in order to save costs, testers usually need to collect a large number of samples before conducting a batch test, and the results can only be qualitative or imprecisely quantitative.

[0006] Electrochemiluminescence immunoassay (ECLI). The chemiluminescence method has a complicated operation process, high testing cost, and the emission intensity is more dependent on environmental factors. In different environmental systems, the curve of emission intensity and time will change greatly, so various external factors must be strictly controlled during detection.

[0007] In addition, these two detection methods require solid phase or electrode support, and both require specific detection instruments. With the continuous improvement of life, people are paying more and more attention to health, and there is an urgent need for a simple, automated and efficient detection method. Summary of the invention

[0008] The technical problem to be solved by the embodiments of the present application is that the detection process of anti-cyclic citrullinated peptide antibodies in the prior art is cumbersome, the detection efficiency is low, the detection accuracy is low, and the detection cost is high.

[0009] In order to solve the above technical problems, the present application provides an anti-cyclic citrullinated peptide antibody assay kit, which adopts the following technical solution:

[0010] Comprising: reagent R1 and reagent R2;

[0011] The components of the reagent R1 include a first buffer, inorganic salt ions, an osmotic pressure regulator, a surfactant and a first preservative;

[0012] The components of the reagent R2 include latex microspheres coated with anti-cyclic citrullinated peptide antigen, a blocking agent, a second preservative, a second buffer and a stabilizer.

[0013] Further, the first buffer is selected from Tris buffer;

[0014] The inorganic salt ions are selected from sucrose;

[0015] The osmotic pressure regulator is selected from sodium chloride;

[0016] The surfactant is selected from Tween 20;

[0017] The first preservative is selected from NaN3;

[0018] The latex microspheres are polystyrene microparticles with carboxyl functional groups;

[0019] The blocking agent is selected from a complex containing triethanolamine, glycine, and casein;

[0020] The second preservative is selected from NaN3;

[0021] The second buffer is selected from boric acid-borax buffer;

[0022] The stabilizer is selected from TritonX-100.

[0023] Furthermore, the concentration of the Tris buffer is 100mmoL / L;

[0024] The concentration of the sucrose is 200mmoL / L;

[0025] The concentration of the sodium chloride is 10 g / L;

[0026] The concentration of Tween 20 is 5 g / L;

[0027] The concentration of NaN3 is 0.7 g / L;

[0028] The polystyrene particles have a concentration of 0.1-0.5 g / L and a diameter of 0.07-0.10 μm;

[0029] The mass ratio of the triethanolamine, the glycine and the casein is 1.5:1:2;

[0030] The concentration of the boric acid-borax buffer is 20mmoL / L;

[0031] The concentration of TritonX-100 is 20 g / L.

[0032] Furthermore, the kit also includes calibrators and quality control products;

[0033] The calibrator comprises anti-cyclic citrullinated peptide antibodies of different concentrations and a third buffer;

[0034] The quality control product includes anti-cyclic citrullinated peptide antibodies of different concentrations and a fourth buffer.

[0035] Further, the third buffer and the fourth buffer are independently selected from at least one of a phosphate buffer, a glycine buffer, a HEPES buffer, a MES buffer, a borate buffer, an acetate buffer and an ammonium chloride buffer;

[0036] The concentrations of the third buffer and the fourth buffer are independently 10 mM-500 mM.

[0037] Furthermore, the calibration product and quality control product also include a stabilizer or a preservative;

[0038] The stabilizer is selected from bovine serum albumin;

[0039] The preservative is selected from NaN3.

[0040] In order to solve the above technical problems, the present application also provides a method for preparing an anti-cyclic citrullinated peptide antibody assay kit, which adopts the following technical solution:

[0041] Prepare reagent R1 and reagent R2, and assemble them to form a test kit;

[0042] Wherein, the components of the reagent R1 include a first buffer, inorganic salt ions, an osmotic pressure regulator, a surfactant and a first preservative;

[0043] The components of the reagent R2 include latex microspheres coated with anti-cyclic citrullinated peptide antigen, a blocking agent, a second preservative, a second buffer and a stabilizer.

[0044] Further, the reagent R2 is prepared by the following steps:

[0045] Preparation of polystyrene microparticles with carboxyl functional groups;

[0046] Adding EDC and NHS to the diluted polystyrene microparticles for reaction to obtain a microsphere mixture;

[0047] Adding the anti-cyclic citrullinated peptide antigen to the microsphere mixture, adjusting the pH value to a preset value, and reacting to obtain an antigen-coated microsphere solution;

[0048] adding a blocking agent to the antigen-coated microsphere solution for reaction;

[0049] The second preservative and the stabilizer are added in sequence to react to obtain latex microspheres coated with anti-cyclic citrullinated peptide antigen, namely, reagent R2.

[0050] Furthermore, the polystyrene microparticles with carboxyl functional groups are prepared by the following steps:

[0051] Add water, styrene, itaconic acid, and ACVA into a flask and mix well;

[0052] The flask was sealed, nitrogen was introduced, and the flask was placed in an oil bath for reaction;

[0053] After a preset time, an initiator is added to react and form polystyrene colloid;

[0054] The polystyrene colloid is centrifuged and washed to obtain polystyrene microparticles with carboxyl functional groups.

[0055] Compared with the prior art, this application has the following beneficial effects:

[0056] The kit provided by the present application optimizes the addition ratio of the substances in each component through the double reagent method of reagent R1 and reagent R2, significantly improves the stability of the reagent, and the stability of the test result is stronger; the latex microspheres coated with anti-cyclic citrullinated peptide antigen in reagent R2 can specifically bind to the analyte, so that it can be rapidly aggregated in a short time when there is a analyte, so that the volume of the antigen-antibody conjugate is increased, and the absorbance change of the solution is more significant, thereby improving the sensitivity of the test. In addition, the kit is easy to operate, can be used on a fully automatic biochemical analyzer, is conducive to large-scale automated detection, has high detection efficiency, is easy to use, and can be promoted and applied. DETAILED DESCRIPTION

[0057] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs; the terms used in the specification of the application herein are only for the purpose of describing specific embodiments and are not intended to limit this application; the terms "including" and "having" and any variations thereof in the specification and claims of this application are intended to cover non-exclusive inclusions. The terms "first", "second", etc. in the specification and claims of this application are used to distinguish different objects, not to describe a specific order.

[0058] Reference to "embodiments" herein means that a particular feature, structure, or characteristic described in conjunction with the embodiments may be included in at least one embodiment of the present application. The appearance of the phrase in various locations in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.

[0059] In order to enable those skilled in the art to better understand the solution of the present application, the technical solution in the embodiments of the present application is clearly and completely described below.

[0060] An embodiment of the present application provides an anti-cyclic citrullinated peptide antibody assay kit, which includes a reagent R1 and a reagent R2; the components of the reagent R1 include a first buffer solution, an inorganic salt ion, an osmotic pressure regulator, a surfactant, and a first preservative; the components of the reagent R2 include latex microspheres coated with an anti-cyclic citrullinated peptide antigen, a blocking agent, a second preservative, a second buffer solution, and a stabilizer.

[0061] The kit of this embodiment is a double-reagent method detection kit.

[0062] In some embodiments, the first buffer is selected from Tris buffer; the inorganic salt ion is selected from sucrose; the osmotic pressure regulator is selected from sodium chloride; the surfactant is selected from Tween 20; and the first preservative is selected from NaN3.

[0063] In some embodiments, the latex microspheres are polystyrene microparticles with carboxyl functional groups; the blocking agent is selected from a complex containing triethanolamine, glycine, and casein; the second preservative is selected from NaN3; the second buffer is selected from boric acid-borax buffer; and the stabilizer is selected from TritonX-100.

[0064] Latex microspheres are polystyrene particles with carboxyl functional groups and do not have any other surface groups. Compared with other ordinary microspheres, these latex microspheres have more stable binding ability when coated with antibodies.

[0065] In some embodiments, the concentration of Tris buffer is 100 mmoL / L; the concentration of sucrose is 200 mmoL / L; the concentration of sodium chloride is 10 g / L; the concentration of Tween 20 is 5 g / L; and the concentration of NaN3 is 0.7 g / L.

[0066] In some embodiments, the concentration of polystyrene microparticles is 0.1-0.5 g / L, and the diameter is 0.07-0.10 μm; the mass ratio of triethanolamine, glycine and casein is 1.5:1:2; the concentration of boric acid-borax buffer is 20 mmoL / L; and the concentration of TritonX-100 (polyethylene glycol octylphenyl ether) is 20 g / L.

[0067] In some embodiments, the kit further comprises calibrators and controls.

[0068] Calibrators are mainly used to calibrate measurement systems, evaluate measurement procedures, or assign values ​​to samples to be tested. Calibrators include different concentrations of anti-cyclic citrullinated peptide antibodies and a third buffer.

[0069] The anti-cyclic citrullinated peptide antibody in the calibrator is a known antibody with different concentrations, illustratively including 6 different concentrations of anti-cyclic citrullinated peptide antibodies, such as but not limited to 2.5 U / mL, 5 U / mL, 10 U / mL, 20 U / mL, 40 U / mL and 80 U / mL.

[0070] In some embodiments, the calibrator can be prepared in liquid form, dry powder, or lyophilized powder form.

[0071] The quality control is used to evaluate or measure the accuracy of the test. In some embodiments, the quality control includes different concentrations of anti-cyclic citrullinated peptide antibodies and a fourth buffer. The concentration of the anti-cyclic citrullinated peptide antibody is, for example but not limited to, 20 U / mL and 40 U / mL.

[0072] In some embodiments, the third buffer and the fourth buffer are each independently selected from at least one of a phosphate buffer, a glycine buffer, a HEPES buffer, a MES buffer, a borate buffer, an acetate buffer, and an ammonium chloride buffer.

[0073] The concentrations of the third buffer and the fourth buffer are independently 10 mM to 500 mM.

[0074] In some embodiments, when the buffer of the calibrator and the quality control is appropriate, the calibrator and the quality control further include a stabilizer or a preservative, wherein the stabilizer is selected from bovine serum albumin (BSA); and the preservative is selected from NaN3.

[0075] Based on the above anti-cyclic citrullinated peptide antibody assay kit, the detection principle is:

[0076] The anti-cyclic citrullinated peptide antigen is coated on a uniform latex microsphere of moderate size. When encountering the corresponding anti-cyclic citrullinated peptide antibody, the antibody will specifically bind to the antigen coated on the latex microsphere, so that the latex microspheres are aggregated and the volume of the antigen-antibody conjugate is increased. A single latex microsphere does not hinder the transmission of light within the incident light wave. When two or more latex microspheres are agglomerated, the transmitted light is reduced. The degree of reduction is proportional to the degree of aggregation of the latex microspheres, and the degree of aggregation of the latex microspheres is proportional to the amount of anti-cyclic citrullinated peptide antibodies to be tested. Therefore, the change in its absorbance value can reflect the content of the antibody to be tested. The change in the absorbance of the solution has a linear relationship with the concentration of the test object within a certain range. According to the standard curve, the content of anti-cyclic citrullinated peptide antibodies in the test sample can be known.

[0077] The kit of the present application uses latex immunoturbidimetry to rapidly detect anti-cyclic citrullinated peptide antibodies, and uses the specific binding of antigen and antibody to rapidly aggregate latex, increase the volume of antigen-antibody conjugates, and thus significantly change the absorbance of the solution, and can quantitatively detect the content of anti-cyclic citrullinated peptide antibodies in human serum. At the same time, the prepared latex microspheres with a highly carboxylated surface do not have any other surface groups. Compared with other ordinary microspheres, such latex microspheres have a more stable binding ability when coated with antibodies, and have fast detection speed, high sensitivity, good accuracy, strong specificity, good stability, and simple operation.

[0078] Based on the above anti-cyclic citrullinated peptide antibody assay kit, the present application also provides a method for preparing an anti-cyclic citrullinated peptide antibody assay kit, the preparation method comprising the following steps:

[0079] Reagent R1 and reagent R2 are prepared and assembled to form a test kit.

[0080] In some embodiments, reagent R2 is prepared by the following steps:

[0081] Preparation of polystyrene microparticles with carboxyl functional groups;

[0082] Adding EDC (1-ethyl-(3-dimethylaminopropyl)carbodiimide) and NHS (sodium salt of N-hydroxysulfosuccinimide) to the diluted polystyrene microparticles for reaction to obtain a microsphere mixture;

[0083] Adding the anti-cyclic citrullinated peptide antigen to the microsphere mixture, adjusting the pH value to a preset value, and reacting to obtain an antigen-coated microsphere solution;

[0084] Adding the blocking agent to the antigen-coated microsphere solution to react;

[0085] The second preservative and the stabilizer are added in sequence to react to obtain latex microspheres coated with anti-cyclic citrullinated peptide antigen, namely, reagent R2.

[0086] As a specific example, reagent R2 is prepared by the following steps:

[0087] 1. Dilute the latex microspheres with pure water to a final concentration of 0.25 g / L, slowly add EDC and NHS to the latex microspheres to a final concentration of 10 mM / L, mix well, and stir at 400 r / min at 37°C for 30-50 min;

[0088] 2. Add anti-cyclic citrullinated peptide antigen to the mixed solution obtained in step 1 to a final concentration of 5 mg / L, adjust the pH value of the mixed solution to 8.5 with boric acid and borax, and stir at 400 r / min at 37°C for 60 min to obtain a mixed solution of latex microspheres coated with antigen;

[0089] 3. Add the blocking agent to the coated latex microsphere mixture and stir at 400 r / min at 37°C for 10 min;

[0090] 4. Finally, NaN3 (second preservative) and TritonX-100 (stabilizer) were added in sequence and stirred at 400 r / min at 37°C for 30 min. After being fully dispersed by ultrasonic instrument, latex particles coated with anti-cyclic citrullinated peptide antigen were obtained.

[0091] In some embodiments, polystyrene microparticles with carboxyl functional groups are prepared by the following steps:

[0092] Add water, styrene, itaconic acid (IA), and ACVA (4,4'-azoazo(4-cyanovaleric acid)) into a flask and mix well;

[0093] The flask was sealed, nitrogen was introduced, and the flask was placed in an oil bath for reaction;

[0094] After a preset time, an initiator is added to react and form polystyrene colloid;

[0095] The polystyrene colloid is centrifuged and washed to obtain polystyrene microparticles with carboxyl functional groups.

[0096] As a specific example, polystyrene microparticles with carboxyl functional groups are prepared by the following steps:

[0097] 1. Add pure water, styrene, IA, and ACVA in a mass ratio of 2500:100:2:1 into a single-necked round-bottom flask and place a magnetic stirring bar;

[0098] 2. Seal the flask with a rubber septum and pass nitrogen into the flask. After 15 minutes, place the liquid in an oil bath at 85°C and stir at a speed of 500 r / min;

[0099] 3.15 minutes later, ACVA was dissolved in 0.2 mol / L sodium hydroxide (28 mg / mL) and added to the mixture as an initiator. The reaction was continued at 85°C and stirred at a speed of 500 r / min for 12 hours to generate a polystyrene colloid (reaction mixture).

[0100] Finally, the reaction mixture was filtered, the prepared polystyrene colloid was centrifuged and washed three times with deionized water to obtain polystyrene microparticles with carboxyl functional groups.

[0101] The microparticles prepared in this example have a high carboxylic acid charge density on their surface without any other surface groups, and are latex microspheres with a highly carboxylated surface and a diameter of about 0.07-0.10 μm.

[0102] In some embodiments, calibrators and quality control products are prepared, and reagent R1, reagent R2, calibrators and quality control products are assembled to obtain a kit.

[0103] Based on the above anti-cyclic citrullinated peptide antibody assay kit, the present application provides a detection method of the anti-cyclic citrullinated peptide antibody assay kit, the steps are as follows:

[0104] Step 1: Reagent preparation

[0105] Reagents R1 and R2 in this kit are both liquid reagents and can be used directly. It is recommended to mix by inversion.

[0106] Step 2: Test conditions

[0107] The optimum temperature for the reaction of this kit with samples is 37°C, and the detection wavelength is 545nm.

[0108] Step 3: Calibration Procedure

[0109] First, use the calibrator provided with this kit to create a calibration curve, that is, perform the calibration operation, with the concentration of the calibrator as the horizontal axis and the corresponding △OD 545 The vertical axis is used, and nonlinear fitting, such as Spline, is used to draw the standard curve.

[0110] Step 4: Quality Control Procedures

[0111] To ensure the reliability of the test results, the quality control material provided with this kit is tested when testing each batch of samples.

[0112] If the quality control fails, please follow the steps below to find out the reason:

[0113] Check whether the parameter settings and light source are correct;

[0114] Check whether the cuvette and sample needle are clean;

[0115] Check water for contamination, bacterial growth can lead to incorrect results;

[0116] Check whether the reaction temperature meets the standard;

[0117] Check the expiration date of the test kit.

[0118] Step 5: Sample testing

[0119] As shown in Table 1, the amounts and order of adding reagent R1, reagent R2 and sample are shown.

[0120] Table 1

[0121]

[0122] Step 6: Calculation of test results

[0123] A calibration curve was prepared by comparing the concentration of the calibrator with the corresponding ΔA, and the concentration of anti-cyclic citrullinated peptide antibodies in the sample was read from the calibration curve through the ΔA of the sample.

[0124] The following is a more specific description of the content of the present application in conjunction with specific embodiments, and further elaboration of the present application, but these embodiments are by no means limiting the present application.

[0125] Example 1

[0126] This example shows the components, packaging and quantity of the anti-cyclic citrullinated peptide antibody assay kit, as shown in Table 2.

[0127] Table 2

[0128]

[0129] Example 2

[0130] This example is a precision evaluation test of the kit of this application.

[0131] 1. Experimental methods

[0132] Under repeatability conditions, the quality control material test kit was tested 10 times with 2 concentrations, and the average value of the measured values ​​was calculated. and standard deviation (SD) and calculated coefficient of variation (CV)

[0133] 2. Experimental results

[0134] Table 3

[0135]

[0136]

[0137] 3. Results Analysis

[0138] As can be seen from the above table, the numerical standard deviation and coefficient of variation of the test kit of Example 1 are significantly smaller than those of the test kits corresponding to Comparative Examples 1 and 2, and have higher intra-batch precision. This indicates that the latex microspheres with high carboxylation surfaces prepared in the present application enable the reagent to react significantly when detecting samples, and the test results are more accurate, which greatly improves the intra-batch precision of the test kit.

[0139] Example 3

[0140] This example is a stability evaluation experiment of the kit

[0141] 1. Experimental methods

[0142] The reagents of Example 1 and Comparative Examples 1 and 2 were placed in the following environments: (1) stored at 2-8°C until the 35th day after opening; (2) stored at 37°C until the 7th day; (3) stored at 2-8°C until the 13th month; under repeatability conditions, the reagents were tested 10 times with the same concentration of quality control products, and the mean and standard deviation (SD) of the measured values ​​and the coefficient of variation (CV) were calculated respectively.

[0143] 2. Experimental results

[0144] Table 4

[0145]

[0146]

[0147]

[0148] 3. Results Analysis

[0149] It can be seen from the above table that the numerical standard deviation and coefficient of variation of the test kit of Example 1 corresponding to all test items are significantly smaller than those of the test kits corresponding to Comparative Examples 1 and 2, and have better stability. This shows that the latex microspheres with high carboxylation surfaces prepared in the present application make the antigen-coated latex complex more stable, optimize the reaction system, and greatly improve the stability of the test kit.

[0150] Embodiment 4:

[0151] This example is an interference evaluation experiment of the kit

[0152] 1. Experimental methods

[0153] The reagents of implementation 1 and comparison 1 and 2 were used to test normal and abnormal samples containing hemoglobin, bilirubin, and fat emulsion (three parallel data in each group): (1) stored at 2-8°C until the 35th day after opening the bottle; (2) stored at 37°C until the 7th day; (3) stored at 2-8°C until the 13th month; under repeatability conditions, the reagents were tested with the same concentration of quality control products for 10 times, and the mean and standard deviation (SD) of the measured values ​​and the coefficient of variation (CV) were calculated respectively.

[0154] 2. Experimental results

[0155] Table 5

[0156]

[0157]

[0158]

[0159]

[0160] 3. Results Analysis

[0161] It can be seen from the above table that the interference effect and relative deviation of the numerical values ​​detected by the kit of Example 1 corresponding to all test items are significantly smaller than those of the kits corresponding to Comparative Examples 1 and 2, and the test results are more stable. This shows that the latex microspheres with high carboxylation surfaces prepared in the present application make the antigen-coated latex complex more resistant to interference in the presence of interfering substances.

[0162] Obviously, the embodiments described above are only a part of the embodiments of the present application, rather than all the embodiments. The preferred embodiments of the present application are given in the specification, but they do not limit the patent scope of the present application. The present application can be implemented in many different forms. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present application more thorough and comprehensive. Although the present application is described in detail with reference to the aforementioned embodiments, for those skilled in the art, it is still possible to modify the technical solutions recorded in the aforementioned specific implementation methods, or to perform equivalent replacement of some of the technical features therein. Any equivalent structure made using the contents of the specification of this application, directly or indirectly used in other related technical fields, is also within the scope of patent protection of this application.

Claims

1. A kit for determining anti-cyclic citrullinated peptide antibodies, characterized in that: include: Reagent R1 and reagent R2; The components of the reagent R1 include a first buffer, inorganic salt ions, an osmotic pressure regulator, a surfactant and a first preservative; The components of the reagent R2 include latex microspheres coated with anti-cyclic citrullinated peptide antigen, a blocking agent, a second preservative, a second buffer and a stabilizer.

2. The anti-cyclic citrullinated peptide antibody assay kit according to claim 1, characterized in that: The first buffer is selected from Tris buffer; The inorganic salt ions are selected from sucrose; The osmotic pressure regulator is selected from sodium chloride; The surfactant is selected from Tween 20; The first preservative is selected from NaN3; The latex microspheres are polystyrene microparticles with carboxyl functional groups; The blocking agent is selected from a complex containing triethanolamine, glycine, and casein; The second preservative is selected from NaN3; The second buffer is selected from a boric acid-borax buffer; The stabilizer is selected from TritonX-100.

3. The anti-cyclic citrullinated peptide antibody assay kit according to claim 2, characterized in that: The concentration of the Tris buffer is 100mmoL / L; The concentration of the sucrose is 200mmoL / L; The concentration of the sodium chloride is 10 g / L; The concentration of Tween 20 is 5 g / L; The concentration of the NaN3 is 0.7 g / L; The polystyrene particles have a concentration of 0.1-0.5 g / L and a diameter of 0.07-0.10 μm; The mass ratio of the triethanolamine, the glycine and the casein is 1.5:1:2; The concentration of the boric acid-borax buffer is 20mmoL / L; The concentration of TritonX-100 is 20 g / L.

4. The anti-cyclic citrullinated peptide antibody assay kit according to any one of claims 1 to 3, characterized in that: The kit also includes calibrators and quality control products; The calibrator comprises anti-cyclic citrullinated peptide antibodies of different concentrations and a third buffer; The quality control product includes anti-cyclic citrullinated peptide antibodies of different concentrations and a fourth buffer.

5. The anti-cyclic citrullinated peptide antibody assay kit according to claim 4, characterized in that: The third buffer and the fourth buffer are independently selected from at least one of a phosphate buffer, a glycine buffer, a HEPES buffer, a MES buffer, a borate buffer, an acetate buffer and an ammonium chloride buffer; The concentrations of the third buffer and the fourth buffer are independently 10 mM-500 mM.

6. The anti-cyclic citrullinated peptide antibody assay kit according to claim 4, characterized in that: The calibrator and quality control product also include a stabilizer or a preservative; The stabilizer is selected from bovine serum albumin; The preservative is selected from NaN3.

7. A method for preparing an anti-cyclic citrullinated peptide antibody assay kit, characterized in that: The following steps are involved: Prepare reagent R1 and reagent R2, and assemble them to form a test kit; Wherein, the components of the reagent R1 include a first buffer, inorganic salt ions, an osmotic pressure regulator, a surfactant and a first preservative; The components of the reagent R2 include latex microspheres coated with anti-cyclic citrullinated peptide antigen, a blocking agent, a second preservative, a second buffer and a stabilizer.

8. The method for preparing the anti-cyclic citrullinated peptide antibody assay kit according to claim 7, characterized in that: The reagent R2 is prepared by the following steps: Preparation of polystyrene microparticles with carboxyl functional groups; Adding EDC and NHS to the diluted polystyrene microparticles for reaction to obtain a microsphere mixture; Adding the anti-cyclic citrullinated peptide antigen to the microsphere mixture, adjusting the pH value to a preset value, and reacting to obtain an antigen-coated microsphere solution; adding a blocking agent to the antigen-coated microsphere solution to react; The second preservative and the stabilizer are added in sequence to react to obtain latex microspheres coated with anti-cyclic citrullinated peptide antigen, namely, reagent R2.

9. The method for preparing the anti-cyclic citrullinated peptide antibody assay kit according to claim 8, characterized in that: The polystyrene microparticles with carboxyl functional groups are prepared by the following steps: Add water, styrene, itaconic acid, and ACVA into a flask and mix well; The flask was sealed, nitrogen was introduced, and the flask was placed in an oil bath for reaction; After a preset time, an initiator is added to react and form polystyrene colloid; The polystyrene colloid is centrifuged and washed to obtain polystyrene microparticles with carboxyl functional groups.

Citation Information

Patent Citations

  • Anti-cyclic citrullinated peptide antibody detection kit

    CN107942067A

  • Anti-cyclic citrullinated peptide antibody determination reagent kit

    CN108614122A

  • Anti-cyclic citrullinated peptide antibody detection kit and preparation method thereof

    CN114878829A

  • Latex enhanced immunoturbidimetry kit, and preparation method and application of latex microsphere solution

    CN115792210A

  • Cross-linkable fine particle, hydrophilization treating agent, method for coating hydrophilic film and hydrophilic film

    JP2005002151A